Hikma Pharmaceuticals Share Price (HIK)
| Bid price | 1,392.00 | Open price | 1,398.00 |
|---|---|---|---|
| Ask price | 1,394.00 | Prev close | 1,395.00 |
| High price | 1,404.34 | Spread | 0.14% |
| Low price | 1,380.67 | Volume | 95,995 |
Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.
Hikma Pharmaceuticals Share Price Chart
Register now for FREE Hikma Pharmaceuticals share price charts
Hikma Pharmaceuticals Share Price Information
| Name | Hikma Pharmaceuticals | Epic | HIK |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology | ISIN | GB00B0LCW083 |
| Activites | Hima Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. | Index | FTSE 250 |
Hikma Pharmaceuticals Key Numbers
| Latest Share Price (p) | 1,393.00 | Net Gearing (%) | 41.19 |
|---|---|---|---|
| Market Capitalisation (£m) | 3,357.03 | Gross Gearing (%) | 44.74 |
| Shares in issue (m) | 240.65 | Debt Ratio | 30.02 |
| P/E Ratio | 20.98 | Debt-to-Equity Ratio | 0.53 |
| Total dividends per share (p) | 33.00 | Assets / Equity Ratio | 1.81 |
| Dividend Yield (%) | 1.52 | Price to book value | 1.39 |
| Dividend cover (x) | 2.02 | ROCE (%) | 6.10 |
| Earning per share (p) | 66.50 | EPS Growth (%) | -47.47 |
| 52 week high / low | 2,703.00 / 1,340.00 | DPS Growth (%) | 3.13 |
Hikma Pharmaceuticals Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 31/05/2017 | TIN | Mazen Darwazah | ED | 38,088 |
| 31/05/2017 | TIN | Said Darwazah | CH | 52,164 |
| 15/05/2017 | TIN | Mazen Darwazah | ED | 30,000 |
| 15/05/2017 | TIN | Said Darwazah | CH | 41,000 |
| 20/12/2016 | BUY | Ali Al-Husry | NED | 140,730 |
Hikma Pharmaceuticals Company News
Holding(s) in Company
RNS Number : 8851L Hikma Pharmaceuticals Plc 24 July 2017 Notification of major interests in shares LONDON, 24 July 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast-growing multinational pharmaceuticals group, announces as follows:...
Total Voting Rights
RNS Number : 0660K Hikma Pharmaceuticals Plc 04 July 2017 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 4 July 2017, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK)...
Holding(s) in Company
RNS Number : 9623J Hikma Pharmaceuticals Plc 03 July 2017 Notification of major interests in shares LONDON, 3 July 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:...
More Hikma Pharmaceuticals Company News >>
Register now for FREE Hikma Pharmaceuticals company news
Hikma Pharmaceuticals Share Price Discussions
Hikma Pharmaceuticals (HIK)
Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...
Register now for FREE Hikma Pharmaceuticals share price discussions